Article Sidebar
Published:
Jul 20, 2021Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Protective effect of punicalagin against intracerebral haemorrhage via improvement in blood-brain barrier integrity, and suppression of reactive oxygen species and NF-κB-mediated NLRP3 inflammasome
Abstract
Purpose: To study the effect of punicalagin in a rodent model of intracerebral haemorrhage (ICH).
Methods: Collagenase type IV (0.2 U) was used to induce ICH in Sprague-Dawley rats. The animals were randomly assigned to 5 treatment groups (n = 24) as follows: group I (normal control animals), group II (ICH control group administered saline), and groups III, IV and V (ICH + punicalagin at doses of 12.5, 25, 50 mg/kg, respectively).
Results: Punicalagin treatment improved brain tissue architecture and blood-brain barrier integrity, and reduced ICH-mediated oxidative stress. It effectively upregulated the expression of Nrf-2/HO-1, and enhanced the activation of NF-kB and NLRP3 inflammasome (p < 0.05). Furthermore, punicalagin significantly down-regulated ICH injury-induced increase in IL-1β and IL-18 (p < 0.05).
Conclusion: These results suggest that punicalagin is a potential therapeutic candidate for the management of ICH.
